Global Biotechnology Contract Manufacturing Market Assessment, By Platform Type [Mammalian-based, Microbial-based], By Product Type [Monoclonal Antibodies, Recombinant Protein, Vaccine, Insulin, Growth Factor, Interferons, Others], By Application Type [Clinical, Commercial], By Therapeutic Area Type [Autoimmune Diseases, Oncology, Metabolic Diseases, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Neurology, Respiratory Disorders, Others], By Region, Opportunities and Forecast, 2017-2031F
Global biotechnology contract manufacturing market is expected to experience rapid growth due to the growing demand for biopharmaceuticals, technical advancements in cell and gene therapies, and advancements in manufacturing technologies.
Home>Industry Reports>Global Biotechnology Contract Manufacturing Market Assessment, Opportunities and Forecast, 2017-2031F
Global biotechnology contract manufacturing market is projected to witness a CAGR of 8.5% during the forecast period 2024-2031, growing from USD 17.69 billion in 2023 to USD 33.97 billion in 2031. The biotechnology contract manufacturing market is expected to thrive under the influence of driving factors like growing demand for biopharmaceuticals and technical advancements in cell and gene therapies. Biopharmaceutical products are complex in nature and require a specialized manufacturing setup, which is not easy to manage for pharmaceutical firms. In such situations, pharmaceutical companies hire contract manufacturing organizations with exclusive expertise and manufacturing capabilities to cater to the market requirements. The growing application areas and demand for novel cell and gene therapy have significantly induced market expansion. Advancements in manufacturing technologies and collaborations between pharmaceutical companies and biologics contract manufacturers are some other major driving forces for market growth. However, the complexities in the biologics and constantly evolving needs of specialized facilities and equipment are the major growth challenges for the market. Additionally, regulatory complications and restrictions pose restraints on market growth. With regularly evolving technology, the contract manufacturers need to stay updated, which hinders the expansion of key players. Despite all the challenges and restraints, the market is expected to grow exponentially in the future.
In October 2023, with the introduction of Expert'Biome CDMO by Lallemand, the company is bolstering its strategic position in the microbiome space through contract development and production operations. By providing extensive services in the healthcare sector, Lallemand Health Solutions hopes to assist partners in the creation of next-generation strains through Expert'Biome. These services include medicine manufacturing, bioprocess scaling, strain research and development, and other production procedures.
Growing Demand for Biopharmaceuticals
The global demand for biopharmaceuticals is growing rapidly due to the increasing prevalence of chronic diseases, a rising elderly population, and the growing awareness of efficiency and easy access to biopharmaceuticals. The increasing demand for advanced biologic drugs, such as gene-based biopharmaceuticals, to treat various diseases is also fueling market growth. As the market witnesses the surge in demand for biopharmaceuticals, the biotechnology contract manufacturing requirements will rise further, in turn, expanding the market growth. Manufacturers are constantly working on new launches and service expansions to better cater to the market needs.
For instance, in July 2023, Kincell Bio, a CDMO specializing in cell therapies, was officially launched with USD 36 million in funding led by Kineticos Ventures. Kincell is a spinoff of Inceptor Bio's CMC, manufacturing, and quality organizations. With its new funding, Kincell plans to accelerate innovative research and clinical trials. The company has acquired a facility and a team in Gainesville, Florida, and intends to expand in other key markets such as Research Triangle Park, Boston, and other customer locations.
Advancements in Manufacturing Technologies
Manufacturing technologies are driving changes in biotech contract manufacturing, leading to improved efficiency, increased customization, and enhanced communication. Automation, flexibility, and supply chain management enhancements have made the manufacturing process more efficient, cost-effective, and reliable. These advancements enable contract manufacturers to produce high-quality products in large quantities, meeting the growing market demand. The growing advancements in personalized medicines and biosimilars further enhance the market traction. For instance, in November 2023, SwiftPharma, a Belgian biotech company specializing in molecular farming, and PlantForm Corporation, a Canadian biopharmaceutical company, entered into a contract manufacturing agreement. Under this agreement, SwiftPharma will manufacture antibodies and proteins for PlantForm's product pipeline. Notably, PlantForm will have non-exclusive access to SwiftPharma's manufacturing expertise, enabling the production of biosimilar pembrolizumab utilizing PlantForm's unique systems and materials.
Dominance of Mammalian-based Platforms
Mammalian cell-based biotechnology creates high-quality proteins that are essential in treating immunological disorders. These products are key in developing antibody treatments for diseases and offer advantages over older methods, such as increased precision and fewer adverse effects. There is a regulatory shift towards replacing animal components in cell growth media used for mammal-derived biotech products. For instance, in May 2023, with an EMA and FDA-compliant, state-of-the-art cGMP manufacturing site in Vilnius, Lithuania, Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), announced the completion of its expansion project for cGMP manufacturing facilities in Waltham, Massachusetts. This noteworthy achievement enhances Northway Biotech's reputation as a major force in the field of biopharmaceuticals. The successful 2020 opening of Northway Biotech's process and analytical development laboratories in Waltham, Massachusetts, is the reason for this latest expansion. Modern cGMP suites are now part of the new facility, which is a major turning point in the company's history.
Monoclonal Antibodies Segment Dominates the Market
The demand for monoclonal antibodies has increased significantly, especially during the COVID-19 pandemic, leading to challenges in manufacturing capacity and global shortages of raw materials. To meet this demand, biopharmaceutical companies had to innovate by forming strategic partnerships with contract manufacturing organizations, securing raw materials in advance and collaborating closely with health authorities and government agencies. The demand for these antibodies continues to rise, leading to innovations in manufacturing practices to meet global needs. For instance, in September 2023, KBI Biopharma, a subsidiary of JSR Life Sciences, introduced SUREmAb. This optimized solution uses the SUREtechnology Platform to produce monoclonal antibodies (mAbs) more efficiently and cost-effectively. By utilizing SUREmAb, biopharmaceutical manufacturers can expedite their development timelines. It enables the creation of a research cell bank (RCB) in nine weeks. Additionally, customers can swiftly transition from DNA to GMP drug substance in as little as eleven months. SUREmAb is designed to attain titers of up to 10 g/L, resulting in lower-cost workflow, enhanced operational efficiency, and improved return on investment.
North America to be the Dominating Region
North America leads the biotechnology contract manufacturing due to several factors. The region has a strong pharmaceutical and biotech industry and the presence of highly advanced manufacturing technologies, making it an attractive market for contract manufacturing. Additionally, the rising demand for biologics and biosimilars, increasing outsourcing of biologics manufacturing among biopharmaceutical companies, growing focus on personalized medicines, increasing collaborations between pharmaceutical companies and biologics contract manufacturers, and advancements in manufacturing technologies are driving the growth of the biotechnology contract manufacturing market in North America.
For instance, in January 2024, Enzene Biosciences established its first fabrication facility in the United States, positioned in Hopewell, New Jersey. Scheduled for completion in June 2024, the site has already gained interest from customers, who have started reserving capacities for constant production. The facility, developed to incorporate Enzene Biosciences' patented EnzeneX persistent production technology, is located within the Princeton West Innovation Campus, a strategic area surrounded by biotech and pharmaceutical companies. This location is ideal, enabling Enzene Biosciences to cater to budding US biotechnology firms seeking expertise in continuous manufacturing.
Future Market Scenario
The biopharmaceutical industry has already adjusted its partnerships with suppliers and contract development and manufacturing organizations (CDMOs) to satisfy humanitarian requirements, and this pattern is anticipated to grow. There will be more collaborations between CMOs, biotech startups, and pharmaceutical giants, which will create a strong ecosystem that can speed up the delivery of life-saving treatments to patients worldwide. Additionally, the future of contract manufacturing in the pharmaceutical industry will likely see pharmaceutical companies and CDMOs working more closely together, sharing expertise, resources, and risks to come up with more innovative and effective solutions.
In October 2023, Advent International and Warburg Pincus, prominent global investors, finalized the previously announced acquisition of Baxter International Inc.'s BioPharma Solutions (BPS) business. Operating as an independent contract development and manufacturing organization (CDMO) under the name Simtra BioPharma Solutions, the business will maintain its current range of solutions and capabilities to ensure the continued supply of essential pharmaceutical products worldwide. According to the definitive agreement, Baxter received USD 4.25 billion in cash after factoring in closing adjustments.
Report Scope
“Biotechnology Contract Manufacturing Market Assessment, Opportunities, and Forecast, 2017-2031F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of the global biotechnology contract manufacturing market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031. Additionally, the report profiles the leading players in the industry mentioning their respective market share, business model, competitive intelligence, etc.
|
Report Attribute |
Details |
|
Base Year of the Analysis |
2023 |
|
Historical Period |
2017-2022 |
|
Forecast Period |
2024-2031 |
|
Projected Growth Rate |
CAGR of 8.5% between 2024 and 2031 |
|
Revenue Forecast in 2031 |
USD 33.97 billion |
|
Segments Covered |
Platform Type, Product Type, Application Type, Therapeutic Area Type |
|
Regions Covered |
North America, Europe, South America, Asia-Pacific, Middle East and Africa |
|
Key Companies Profile |
Catalent Inc., Lonza Group Ag, Patheon N.V. (Thermo Fisher Scientific Inc.), Abzena Plc., Sandoz International GmbH (Novartis AG), Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings), Baxter Pharmaceutical Solutions LLC (Baxter Inc.), AbbVie Contract Manufacturing (AbbVie Inc.), Samsung Biologics Co. Ltd., Pfizer Centre Source Ltd (Pfizer Inc.) |
|
Customization Scope |
15% free report customization with purchase |
|
Pricing and Purchase Options |
Avail the customized purchase options to fulfill your precise research needs |
|
Delivery Format |
PDF and Excel through email (subject to the license purchased) |
In the report, the global biotechnology contract manufacturing market has been segmented into the following categories:
· By Platform Type
o Mammalian-based
o Microbial-based
· By Product Type
o Monoclonal Antibodies
o Recombinant Protein
o Vaccine
o Insulin
o Growth factor
o Interferons
o Others
· By Application Type
o Clinical
o Commercial
· By Therapeutic Area Type
o Autoimmune Diseases
o Oncology
o Metabolic Diseases
o Ophthalmology
o Cardiovascular Diseases
o Infectious Diseases
o Neurology
o Respiratory Disorders
o Others
· By Region
o North America
o Europe
o Asia-Pacific
o South America
o Middle East and Africa
Key Players Landscape and Outlook
Catalent Inc., Lonza Group Ag, Patheon N.V. (Thermo Fisher Scientific Inc.), Abzena Plc., Sandoz International GmbH (Novartis AG), Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings), and Baxter Pharmaceutical Solutions LLC are some of the renowned players in the biotechnology contract manufacturing market. These companies play a crucial role in offering specialized services for the manufacturing of biological drugs, particularly biologics, drug substance, and drug product, catering to the needs of pharmaceutical and biotechnological companies globally.
In February 2024, Novo Holdings, a subsidiary of Novo Nordisk, plans to purchase Catalent, a well-established contract manufacturing organization, for USD 16.5 billion. The acquisition will involve Novo Holdings paying USD 63.50 in cash for each outstanding share of Catalent, reflecting a 16.5% increase above the current market value. The transaction is projected to be finalized around the end of 2024.
Key Players Operating in the Global Biotechnology Contract Manufacturing Market are:
· Catalent Inc.
· Lonza Group Ag
· Patheon N.V. (Thermo Fisher Scientific Inc.)
· Abzena Plc.
· Sandoz International GmbH (Novartis AG)
· Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings)
· Baxter Pharmaceutical Solutions LLC (Baxter Inc.)
· AbbVie Contract Manufacturing (AbbVie Inc.)
· Samsung Biologics Co. Ltd.
· Pfizer Centre Source Ltd (Pfizer Inc.)
Markets and Data’s report answers the following questions:
· What is the current and future market size of the product/service in question globally or specific to different countries?
· How are the markets divided into different product/service segments and the market size and growth of each segment?
· What is the market potential of different product segments and their investment case?
· How are the markets predicted to develop in the future and what factors will drive or inhibit growth?
· What is the business environment and regulatory landscape specific to the product/service?
If you can't find what you're searching for or have any custom requirements for global biotechnology contract manufacturing market, you may approach our team at info@marketsandata.com
Table of Contents
1. Research Methodology
2. Project Scope & Definitions
3. Executive Summary
4. Global Biotechnology Contract Manufacturing Market Outlook, 2017-2031F
4.1. Market Size & Forecast
4.1.1. By Value
4.1.2. By Volume
4.2. By Platform Type
4.2.1.Mammalian-based
4.2.2.Microbial-based
4.3. By Product Type
4.3.1.Monoclonal Antibodies
4.3.2.Recombinant Protein
4.3.3.Vaccine
4.3.4.Insulin
4.3.5.Growth factor
4.3.6.Interferons
4.3.7.Others
4.4. By Application Type
4.4.1.Clinical
4.4.2.Commercial
4.5. By Therapeutic Area Type
4.5.1.Autoimmune Diseases
4.5.2.Oncology
4.5.3.Metabolic Diseases
4.5.4.Ophthalmology
4.5.5.Cardiovascular Diseases
4.5.6.Infectious Diseases
4.5.7.Neurology
4.5.8.Respiratory Disorders
4.5.9.Others
4.6. By Region
4.6.1. North America
4.6.2. Europe
4.6.3. Asia-Pacific
4.6.4. South America
4.6.5. Middle East and Africa
4.7. By Company Market Share (%), 2023
5. Global Biotechnology Contract Manufacturing Market Outlook, By Region, 2017-2031F
5.1. North America*
5.1.1.Market Size & Forecast
5.1.1.1. By Value
5.1.1.2. By Volume
5.1.2.By Platform Type
5.1.2.1. Mammalian-based
5.1.2.2. Microbial-based
5.1.3.By Product Type
5.1.3.1. Monoclonal Antibodies
5.1.3.2. Recombinant Protein
5.1.3.3. Vaccine
5.1.3.4. Insulin
5.1.3.5. Growth factor
5.1.3.6. Interferons
5.1.3.7. Others
5.1.4.By Application Type
5.1.4.1. Clinical
5.1.4.2. Commercial
5.1.5.By Therapeutic Area Type
5.1.5.1. Autoimmune Diseases
5.1.5.2. Oncology
5.1.5.3. Metabolic Diseases
5.1.5.4. Ophthalmology
5.1.5.5. Cardiovascular Diseases
5.1.5.6. Infectious Diseases
5.1.5.7. Neurology
5.1.5.8. Respiratory Disorders
5.1.5.9. Others
5.1.6.United States*
5.1.6.1. Market Size & Forecast
5.1.6.1.1. By Value
5.1.6.1.2. By Volume
5.1.6.2. By Platform Type
5.1.6.2.1. Mammalian-based
5.1.6.2.2. Microbial-based
5.1.6.3. By Product Type
5.1.6.3.1. Monoclonal Antibodies
5.1.6.3.2. Recombinant Protein
5.1.6.3.3. Vaccine
5.1.6.3.4. Insulin
5.1.6.3.5. Growth factor
5.1.6.3.6. Interferons
5.1.6.3.7. Others
5.1.6.4. By Application Type
5.1.6.4.1. Clinical
5.1.6.4.2. Commercial
5.1.6.5. By Therapeutic Area Type
5.1.6.5.1. Autoimmune Diseases
5.1.6.5.2. Oncology
5.1.6.5.3. Metabolic Diseases
5.1.6.5.4. Ophthalmology
5.1.6.5.5. Cardiovascular Diseases
5.1.6.5.6. Infectious Diseases
5.1.6.5.7. Neurology
5.1.6.5.8. Respiratory Disorders
5.1.6.5.9. Others
5.1.7.Canada
5.1.8.Mexico
*All segments will be provided for all regions and countries covered
5.2. Europe
5.2.1.Germany
5.2.2.France
5.2.3.Italy
5.2.4.United Kingdom
5.2.5.Russia
5.2.6.Netherlands
5.2.7.Spain
5.2.8.Turkey
5.2.9.Poland
5.3. Asia-Pacific
5.3.1.India
5.3.2.China
5.3.3.Japan
5.3.4.Australia
5.3.5.Vietnam
5.3.6.South Korea
5.3.7.Indonesia
5.3.8.Philippines
5.4. South America
5.4.1.Brazil
5.4.2.Argentina
5.5. Middle East & Africa
5.5.1.Saudi Arabia
5.5.2.UAE
5.5.3.South Africa
6. Market Mapping, 2023
6.1. By Platform Type
6.2. By Product Type
6.3. By Application Type
6.4. By Therapeutic Area Type
6.5. By Region
7. Macro Environment and Industry Structure
7.1. Demand Supply Analysis
7.2. Import Export Analysis
7.3. Value Chain Analysis
7.4. PESTEL Analysis
7.4.1. Political Factors
7.4.2. Economic System
7.4.3. Social Implications
7.4.4. Technological Advancements
7.4.5. Environmental Impacts
7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
7.5. Porter’s Five Forces Analysis
7.5.1. Supplier Power
7.5.2. Buyer Power
7.5.3. Substitution Threat
7.5.4. Threat from New Entrant
7.5.5. Competitive Rivalry
8. Market Dynamics
8.1. Growth Drivers
8.2. Growth Inhibitors (Challenges and Restraints)
9. Regulatory Framework and Innovation
9.1. Patent Landscape
9.2. Innovations/Emerging Technologies
10. Key Players Landscape
10.1. Competition Matrix of Top Five Market Leaders
10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
10.4. SWOT Analysis (For Five Market Players)
11. Pricing Analysis
12. Case Studies
13. Key Players Outlook
13.1. Catalent Inc.
13.1.1. Company Details
13.1.2. Key Management Personnel
13.1.3. Products & Services
13.1.4. Financials (As reported)
13.1.5. Key Market Focus & Geographical Presence
13.1.6. Recent Developments
13.2. Lonza Group Ag
13.3. Patheon N.V. (Thermo Fisher Scientific Inc.)
13.4. Abzena Plc.
13.5. Sandoz International GmbH (Novartis AG)
13.6. Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings)
13.7. Baxter Pharmaceutical Solutions LLC (Baxter Inc.)
13.8. AbbVie Contract Manufacturing (AbbVie Inc.)
13.9. Samsung Biologics Co. Ltd.
13.10. Pfizer Centre Source Ltd (Pfizer Inc.)
*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.
14. Strategic Recommendations
15. About Us & Disclaimer
List of Figures
Figure 1. Global Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
Figure 2. Global Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
Figure 3. Global Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
Figure 4. Global Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
Figure 5. Global Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
Figure 6. Global Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
Figure 7. Global Biotechnology Contract Manufacturing Market Share (%), By Region, 2017-2031F
Figure 8. North America Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
Figure 9. North America Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
Figure 10. North America Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
Figure 11. North America Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
Figure 12. North America Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
Figure 13. North America Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
Figure 14. North America Biotechnology Contract Manufacturing Market Share (%), By Country, 2017-2031F
Figure 15. United States Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
Figure 16. United States Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
Figure 17. United States Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
Figure 18. United States Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
Figure 19. United States Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
Figure 20. United States Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
Figure 21. Canada Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
Figure 22. Canada Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
Figure 23. Canada Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
Figure 24. Canada Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
Figure 25. Canada Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
Figure 26. Canada Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
Figure 27. Mexico Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
Figure 28. Mexico Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
Figure 29. Mexico Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
Figure 30. Mexico Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
Figure 31. Mexico Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
Figure 32. Mexico Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
Figure 33. Europe Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
Figure 34. Europe Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
Figure 35. Europe Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
Figure 36. Europe Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
Figure 37. Europe Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
Figure 38. Europe Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
Figure 39. Europe Biotechnology Contract Manufacturing Market Share (%), By Country, 2017-2031F
Figure 40. Germany Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
Figure 41. Germany Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
Figure 42. Germany Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
Figure 43. Germany Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
Figure 44. Germany Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
Figure 45. Germany Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
Figure 46. France Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
Figure 47. France Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
Figure 48. France Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
Figure 49. France Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
Figure 50. France Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
Figure 51. France Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
Figure 52. Italy Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
Figure 53. Italy Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
Figure 54. Italy Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
Figure 55. Italy Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
Figure 56. Italy Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
Figure 57. Italy Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
Figure 58. United Kingdom Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
Figure 59. United Kingdom Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
Figure 60. United Kingdom Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
Figure 61. United Kingdom Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
Figure 62. United Kingdom Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
Figure 63. United Kingdom Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
Figure 64. Russia Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
Figure 65. Russia Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
Figure 66. Russia Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
Figure 67. Russia Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
Figure 68. Russia Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
Figure 69. Russia Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
Figure 70. Netherlands Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
Figure 71. Netherlands Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
Figure 72. Netherlands Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
Figure 73. Netherlands Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
Figure 74. Netherlands Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
Figure 75. Netherlands Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
Figure 76. Spain Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
Figure 77. Spain Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
Figure 78. Spain Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
Figure 79. Spain Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
Figure 80. Spain Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
Figure 81. Spain Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
Figure 82. Turkey Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
Figure 83. Turkey Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
Figure 84. Turkey Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
Figure 85. Turkey Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
Figure 86. Turkey Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
Figure 87. Turkey Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
Figure 88. Poland Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
Figure 89. Poland Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
Figure 90. Poland Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
Figure 91. Poland Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
Figure 92. Poland Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
Figure 93. Poland Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
Figure 94. South America Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
Figure 95. South America Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
Figure 96. South America Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
Figure 97. South America Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
Figure 98. South America Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
Figure 99. South America Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
Figure 100. South America Biotechnology Contract Manufacturing Market Share (%), By Country, 2017-2031F
Figure 101. Brazil Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
Figure 102. Brazil Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
Figure 103. Brazil Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
Figure 104. Brazil Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
Figure 105. Brazil Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
Figure 106. Brazil Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
Figure 107. Argentina Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
Figure 108. Argentina Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
Figure 109. Argentina Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
Figure 110. Argentina Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
Figure 111. Argentina Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
Figure 112. Argentina Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
Figure 113. Asia-Pacific Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
Figure 114. Asia-Pacific Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
Figure 115. Asia-Pacific Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
Figure 116. Asia-Pacific Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
Figure 117. Asia-Pacific Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
Figure 118. Asia-Pacific Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
Figure 119. Asia-Pacific Biotechnology Contract Manufacturing Market Share (%), By Country, 2017-2031F
Figure 120. India Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
Figure 121. India Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
Figure 122. India Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
Figure 123. India Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
Figure 124. India Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
Figure 125. India Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
Figure 126. China Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
Figure 127. China Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
Figure 128. China Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
Figure 129. China Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
Figure 130. China Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
Figure 131. China Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
Figure 132. Japan Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
Figure 133. Japan Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
Figure 134. Japan Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
Figure 135. Japan Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
Figure 136. Japan Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
Figure 137. Japan Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
Figure 138. Australia Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
Figure 139. Australia Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
Figure 140. Australia Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
Figure 141. Australia Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
Figure 142. Australia Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
Figure 143. Australia Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
Figure 144. Vietnam Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
Figure 145. Vietnam Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
Figure 146. Vietnam Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
Figure 147. Vietnam Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
Figure 148. Vietnam Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
Figure 149. Vietnam Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
Figure 150. South Korea Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
Figure 151. South Korea Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
Figure 152. South Korea Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
Figure 153. South Korea Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
Figure 154. South Korea Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
Figure 155. South Korea Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
Figure 156. Indonesia Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
Figure 157. Indonesia Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
Figure 158. Indonesia Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
Figure 159. Indonesia Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
Figure 160. Indonesia Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
Figure 161. Indonesia Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
Figure 162. Philippines Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
Figure 163. Philippines Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
Figure 164. Philippines Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
Figure 165. Philippines Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
Figure 166. Philippines Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
Figure 167. Philippines Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
Figure 168. Middle East & Africa Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
Figure 169. Middle East & Africa Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
Figure 170. Middle East & Africa Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
Figure 171. Middle East & Africa Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
Figure 172. Middle East & Africa Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
Figure 173. Middle East & Africa Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
Figure 174. Middle East & Africa Biotechnology Contract Manufacturing Market Share (%), By Country, 2017-2031F
Figure 175. Saudi Arabia Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
Figure 176. Saudi Arabia Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
Figure 177. Saudi Arabia Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
Figure 178. Saudi Arabia Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
Figure 179. Saudi Arabia Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
Figure 180. Saudi Arabia Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
Figure 181. UAE Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
Figure 182. UAE Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
Figure 183. UAE Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
Figure 184. UAE Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
Figure 185. UAE Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
Figure 186. UAE Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
Figure 187. South Africa Biotechnology Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
Figure 188. South Africa Biotechnology Contract Manufacturing Market, By Volume, In Million Units, 2017-2031F
Figure 189. South Africa Biotechnology Contract Manufacturing Market Share (%), By Platform Type, 2017-2031F
Figure 190. South Africa Biotechnology Contract Manufacturing Market Share (%), By Product Type, 2017-2031F
Figure 191. South Africa Biotechnology Contract Manufacturing Market Share (%), By Application Type, 2017-2031F
Figure 192. South Africa Biotechnology Contract Manufacturing Market Share (%), By Therapeutic Area Type, 2017-2031F
Figure 193. By Platform Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 194. By Product Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 195. By Application Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 196. By Therapeutic Area Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023
List of Tables
Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects
Frequently Asked Questions
What are the regions covered in the final report for the global biotechnology contract manufacturing market?
Who are the key players operating in the global biotechnology contract manufacturing market?
What are the major drivers influencing the growth of the global biotechnology contract manufacturing market?
What is the market size and growth rate of the global biotechnology contract manufacturing market?
See Related Reports
Global Suspension Arm Bushes Market Assessment, Opportunities and Forecast, 2017-2031F
The global suspension arm bushes market is expected to grow in the future owing to therising sales of used cars and increasing consumption through auto workshops and maintenance facilities.....Read More
Published on
May 2024
4,500
Global Trailing and Link Arm Bushes Market Assessment, Opportunities and Forecast, 2017-2031F
Increased demand for quieter vehicles along with automakers expanding their workshops are anticipated to fuel the global trailing and link arm bushes market growth.....Read More
Published on
May 2024
4,500
Global Bakery Products Market Assessment, Opportunities and Forecast, 2017-2031F
Global bakery products market size is driven by rising demand for vegan bakery options, growing sustainability trend, and preference for dietetic bakery options.....Read More
Published on
May 2024
4,500
Global Craft Beer Market Assessment, Opportunities and Forecast, 2017-2031F
Global craft beer market is driven by changing consumer preferences, sustainable beer production, and rising trend of e-commerce in craft beer market.....Read More
Published on
May 2024
4,500
Purchase Options
USD ($)
i
3,000
i
4,500
i
5,700
i
8,200
Tired of Searching?
Looking for Customization?
Some other doubt?
Need insights from a cohort?
REACH US
